News

The rapidly fast-spreading B.1.1.7 lineage, a variant strain of SARS-CoV-2 detected initially in the UK, has ten mutations located in the spike protein. The two firms had earlier

Akron Biotech will produce the Human AB Serum using Octapharma’s solvent-detergent treated human plasma, Octaplas. The Octaplas viral inactivation and production process includes several independent and complementary steps

As part of the development, Gritstone and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have signed an agreement to

Novartis and GSK have agreed to provide £2.8m ($3.6m) for the Africa Genomic Research Approach for Diversity and Optimizing Therapeutics (GRADIENT) project (Project Africa GRADIENT), over the next

The companies will leverage Cure Genetics’ VELP platform to develop the vectors. Under the partnership, Boehringer’s experience in disease biology and gene therapy development will be combined with

Etana now has the right to sell BYVASDA in the country and in return, Innovent Biologics will receive milestones for the development and commercialisation along with double-digit royalties

The viral vector manufacturing arm of Novasep offers contract manufacturing services for vaccines and therapies to biotechnology and biopharma companies. Established over 20 years ago, the business has

The phase 3 study of Sputnik V will be conducted on 1500 subjects as part of the randomized, double-blind, parallel-group, placebo-controlled study in India. Earlier, the Data and

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced,